Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Biodesix (BDSX) Research & Development: 2019-2025

Historic Research & Development for Biodesix (BDSX) over the last 6 years, with Sep 2025 value amounting to $3.0 million.

  • Biodesix's Research & Development rose 17.47% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.5 million, marking a year-over-year increase of 27.79%. This contributed to the annual value of $9.6 million for FY2024, which is 4.30% down from last year.
  • Biodesix's Research & Development amounted to $3.0 million in Q3 2025, which was down 8.47% from $3.3 million recorded in Q2 2025.
  • Over the past 5 years, Biodesix's Research & Development peaked at $3.6 million during Q4 2022, and registered a low of $1.9 million during Q4 2023.
  • For the 3-year period, Biodesix's Research & Development averaged around $2.6 million, with its median value being $2.6 million (2024).
  • Its Research & Development has fluctuated over the past 5 years, first skyrocketed by 57.71% in 2021, then tumbled by 47.01% in 2023.
  • Over the past 5 years, Biodesix's Research & Development (Quarterly) stood at $2.9 million in 2021, then grew by 25.00% to $3.6 million in 2022, then crashed by 47.01% to $1.9 million in 2023, then climbed by 27.79% to $2.4 million in 2024, then rose by 17.47% to $3.0 million in 2025.
  • Its last three reported values are $3.0 million in Q3 2025, $3.3 million for Q2 2025, and $2.9 million during Q1 2025.